COMPLETE LISTING OF CLAIMS

- (Original) A method of treating patients who have diseases characterized bone loss comprising the step of administering to said patient an amount of TRANCE/RANK inhibitors effective to inhibit osteoclastogenesis and/or osteoclast function.
- 2. (Original) The method of claim 1 wherein said TRANCE/RANK inhibitor is a compound having the Formula I wherein:

R₁, and R₂ are, independently, selected from the group consisting of -H, - OCH₃, -CHZCH₃, -t-butyl, 3-carboxy-4-chlorophenylamino, -N-(CH₂CH₂OH)₂, and -O(O)C-Ph;

R₃ is selected from the group consisting of -H, ethyl, -OCH3, -Cl, Br, F, 3carboxy-4-chlorophenylamino, -N-(CH₂CH₂0H)₂, -t-butyl, and -OC(O)-Ph, and is not limited to attachment at any certain position on the phenyl ring to which it is attached; and

R₄ is selected from the group consisting of -Br,-Cl, and -F.

- 3. (Original) The method of claim 2 wherein R₃ is attached at either the 1 or 4 position of the 15 phenyl ring.
- 4. (Original) The method of claim 1 wherein

 R_1 , R_2 , and R_3 are -OCH₃, R_3 is attached at the 4 position, R_4 is -Cl; R_1 , and R_2 are methyl, R_3 is ethyl, attached at the 4 position, R_4 is -Cl R_1 , and R_2 are -OCH₃, R_3 is -Cl, attached at the 2 position, R_4 is -Cl; R_1 , and R_2 are -OCH₃ and R_3 is H, R_4

is -Cl; R_1 , is H, R_2 and R_3 are 3-carboxy-4-chlorophenylamino, and R_3 is attached at the 4 position, R_4 Is -Cl; R, and R_2 are -N(CH₂CH₂OH)₂, R_3 is Cl, attached at the 4 position, R_4 is -Cl; R_1 , R_2 , and R_3 are *t*-butyl, R_3 is attached at the 4 position, R_4 is -Cl; R_1 , is -OCH₃, R_2 and R_3 are H, R_4 is Cl; or R_3 , R_4 and R_5 are benzoate, R_5 is attached at the 4 position, R_4 is -Br.

- 5. (Original) The method of claim 1 wherein said TRANCE/RANK inhibitor is selected from the group consisting I-A, I-B, I-C, I-D, I-E, I-F, I-G, I-H and I-I.
- 6. (Original) The method of claim 1 wherein said TRANCE/RANK inhibitor is a compound having the Formula II wherein:

R₁ is selected from the group consisting of -diphenylchloro methyl, -di(4chlorophenyl)chloro methyl, and 4-(diphenylchloromethyl)phenyl; and R₂, R₃, R₄ are independently selected from the group consisting of -Br, -Cl, and -F.

- 7. (Original) The method of claim 6 wherein R_2 , R_3 , R_4 are each -Cl.
- 8. (Original) The method of claim 1 wherein the TRANCEIRANK inhibitor is selected from the group consisting compounds II-A, II-B, II-C and II-D.
- 9. (Original) The method of claim 1 wherein said inhibitor is a compound having Formula III wherein:

R₁ = (N0₂)₂, O(CO)CH₃, OH, O(CO)CH₃, O(CO)(CH₂)₂COOH, O(CO)CH₂Br, O(CO)CH₂CI, O(CO)CH₂N(CH₃)₃, or OC₅H₉0; R₂= CH₂O(NO₂), CHO, CH₂O(NO₂), CN, CH₃, COOH, CHNOH,
CH₂0(CO)(CH₂)₂COOH, CHN(NH)CONH₂, CHN(NH)C₆H₅,
CHN(CH₂)C₆H₅, CH₂N(CH₂)₂OH, CH₂NC₆H₅, or
CH₂N(NH)CSNH₂;

 $R_3 = OH$, or H;

 $R_4 = CH_3$;

 $R_5 = OH;$

 $R_6 = C_4H_3O_2$, N(NHCO)C₆H₄Cl, N(NHCO)C₆H₄F, COOH, O, COCH₃, CH(CH₃)(CH₂)₂C00H, CH(CH₃)(CH₂)₂C00CH₃, O(CO)C₆H₅, or OH;

 R_{7} ,= O(CO)CH₂N(CH₃)₃, or O(CO)CH₃;

 $R_8 = OH;$

R₉= O, or OH; and Rio=O

 $R_{10} = O$.

- 10. (Original) The method of claim 1 wherein the inhibitor is selected from the group consisting compounds III-1 to III-31.
- 11. (Original) The method of claim 1 wherein said inhibitor is a compound having Formula IV wherein:

 R_1 , = O(CO)(CH₂)₂COOH, or O(CO)CH₂Br; and

 $R_2 = O(CO)(CH_2)_2COOH$, or $O(CO)CH_2Br$.

12. (Original) The method of claim 1 wherein the inhibitor is selected from the group consisting compounds IV-1 and IV-2.

13. (Original) The method of claim 1 wherein said inhibitor is a compound having Formula V wherein:

$$R_1$$
 = O, OH, or O(CO)CH₃;
 R_2 = O(CO)CH₃, OH, CO(CH₃), or CO(CH₂)O(CO)CH₃;
 R_3 = CH₃, or OH; and
 R_4 = O(CO)CH₂C₆H₄I, or CH₃.

- 14. (Original) The method of claim 1 wherein the inhibitor is selected from the group consisting compounds V-1 and V-5
- 15. (Original) The method of claim 1 wherein said inhibitor is a compound having Formula VI wherein:

$$\begin{split} R_1 &= O(CO)CH_3, \, OH, \, or \, O(CO)(CH_2)_2COOH; \\ R_2 &= CH_3; \\ R_3 &= O, \, or \, OH; \\ R_4 &= CH_3; \\ R_5 &= C_9H_{13}COCH_3, \, C_9H_{13}(CH_2CH_3)(CH_2OH), \\ C_9H_{13}(CH_2CH_3)(CH_2000CH_3), \, C_9H_{13}(CH_2CH_3)(CH_2OCO(CH_2)_2COOH), \, C_9H_{13}(CH_2CH_3)(COOH), \, or \\ C_8H_7O(CH_3)(C_4H_90CH_3); \\ R_6 &= CH_3; \\ R_7 &= O, \, or \, H; \end{split}$$

_{R8}= CH₃;

$$R_9 = (CH_3)_2$$
; and

 $R_{10}=Br.$

16. (Original) The method of claim 1 wherein the inhibitor is selected from the group consisting compounds VI-1 and VI-11.

6

17. (Original) The method of claim 1 wherein the inhibitor is selected from the group consisting compounds VII, VIII IX, X, XI and XII.

Claims 18-43 (Cancelled)

* * * * *